Abcellera Biologics Inc (ABCL)

$5.26 +0.02 (0.38%)
Market Cap 1.60B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 3,694,700
Avg Vol 7,310,530
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 13%
Beta 1.18
Analysts Strong Sell
Price Target $10.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
tranq19
tranq19 Jun. 16 at 4:12 PM
$ABCL just a mere $500K buyat 11:58
0 · Reply
8008track
8008track Jun. 16 at 4:06 PM
$ABCL wow - that volume is insane
0 · Reply
tradersunion353
tradersunion353 Jun. 16 at 2:36 PM
$ABCL Phase 2 Data leaked and is already bad?? why would any stock drop 30-40% on phase 1 data And all of a sudden we see pumpers overhyping this scam Shady very shady......
0 · Reply
DeMampCamp
DeMampCamp Jun. 16 at 2:34 PM
$ABCL Short timers starting to finally sell out so they can move it to the overpriced SpaceX?
1 · Reply
tradersunion353
tradersunion353 Jun. 16 at 2:29 PM
$ABCL Paid pumpers aka clowns - how is you adding and loading on this scam working? 3 dollar next stop If you believe in DEMAMP clown and few other paid pumpers you will lose everything
0 · Reply
JennyRowes
JennyRowes Jun. 16 at 12:44 PM
$ABCL https://www.nytimes.com/2026/06/15/well/menopause-hormone-therapy-breast-cancer.html?unlocked_article_code=1.qVA.Mvh3.c2Z2wDdOTjnc&smid=url-share
0 · Reply
tradersunion353
tradersunion353 Jun. 16 at 12:31 PM
$ABCL no matter how much you guys are paid but you guys are overdone pumping this POS end of the day stock price matters
0 · Reply
tradersunion353
tradersunion353 Jun. 16 at 11:25 AM
$ABCL overhypee junk will be dropping to $1 after phassee 2 data same paid pumpers will come out likr maggots and keep cheerleading we are adding and loading we dont care if it goes to zero what kind of sick mentality is this?
0 · Reply
Money_maker777
Money_maker777 Jun. 15 at 9:38 PM
$ABCL It already moved from $3 to $6 in six weeks. Saying it ‘won’t move’ after a 100% run is wild.
1 · Reply
Money_maker777
Money_maker777 Jun. 15 at 9:37 PM
$ABCL Stocks cool off after big runs. That’s structure. Only amateurs confuse consolidation with collapse.
0 · Reply
Latest News on ABCL
AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 11 days ago

AbCellera appoints Victor Sandor to board of directors

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 5, 2026, 9:00 AM EDT - 11 days ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:40 AM EDT - 12 days ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 4 weeks ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 5 weeks ago

AbCellera price target raised to $8 from $7 at Stifel

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Earnings release: Q1 2026

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Quarterly report: Q1 2026

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Slides: Q1 2026

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 11, 2026, 4:05 PM EDT - 5 weeks ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 7, 2026, 4:05 PM EDT - 5 weeks ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 6 weeks ago

AbCellera initiated with an Overweight at Cantor Fitzgerald

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 6 weeks ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 6 weeks ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 21, 2026, 1:30 PM EDT - 7 weeks ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 20, 2026, 9:00 AM EDT - 2 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 2 months ago

AbCellera initiated with a Buy at JonesResearch

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 1, 2026, 4:05 PM EDT - 2 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 17, 2026, 4:30 PM EDT - 3 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 3 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Annual report: Q4 2025

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Earnings release: Q4 2025

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Slides: Q4 2025

AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 3 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year

AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 3 months ago

AbCellera Reports Full Year 2025 Business Results

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Feb 11, 2026, 4:05 PM EST - 4 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 22, 2026, 4:05 PM EST - 5 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 5 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 5 months ago

AbCellera Biologics Slides: Corporate presentation

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

2026-01-12T14:36:23.000Z - 5 months ago

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Jan 12, 2026, 9:00 AM EST - 5 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

2025-12-18T14:20:19.000Z - 6 months ago

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

BRKR

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 6 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 6 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:00 AM EST - 6 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 7 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 7 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera downgraded to Market Perform from Outperform at Leerink

2025-11-07T11:16:20.000Z - 7 months ago

AbCellera downgraded to Market Perform from Outperform at Leerink

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Quarterly report: Q3 2025

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings release: Q3 2025

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Slides: Q3 2025

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 7 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera appoints Sarah Noonberg as Chief Medical Officer

2025-09-10T13:20:54.000Z - 9 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 9 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 5, 2025, 9:30 AM EDT - 10 months ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

AbCellera doses first participants in Phase 1 trial of ABCL575

2025-08-27T13:20:26.000Z - 10 months ago

AbCellera doses first participants in Phase 1 trial of ABCL575

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 10 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera price target raised to $7 from $5 at BMO Capital

2025-08-08T13:26:29.000Z - 11 months ago

AbCellera price target raised to $7 from $5 at BMO Capital

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Quarterly report: Q2 2025

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings release: Q2 2025

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Slides: Q2 2025

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 11 months ago

AbCellera Biologics Slides: Corporate Presentation

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 11:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

Sep 5, 2024, 3:00 PM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024

AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024

AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024

AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 2 years ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 3:20 PM EDT - 2 years ago

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024

AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024

AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024

AbCellera Biologics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference

Apr 16, 2024, 10:00 AM EDT - 2 years ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

AbCellera Biologics Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 20, 2024, 11:15 AM EDT - 2 years ago

AbCellera Biologics Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

tranq19
tranq19 Jun. 16 at 4:12 PM
$ABCL just a mere $500K buyat 11:58
0 · Reply
8008track
8008track Jun. 16 at 4:06 PM
$ABCL wow - that volume is insane
0 · Reply
tradersunion353
tradersunion353 Jun. 16 at 2:36 PM
$ABCL Phase 2 Data leaked and is already bad?? why would any stock drop 30-40% on phase 1 data And all of a sudden we see pumpers overhyping this scam Shady very shady......
0 · Reply
DeMampCamp
DeMampCamp Jun. 16 at 2:34 PM
$ABCL Short timers starting to finally sell out so they can move it to the overpriced SpaceX?
1 · Reply
tradersunion353
tradersunion353 Jun. 16 at 2:29 PM
$ABCL Paid pumpers aka clowns - how is you adding and loading on this scam working? 3 dollar next stop If you believe in DEMAMP clown and few other paid pumpers you will lose everything
0 · Reply
JennyRowes
JennyRowes Jun. 16 at 12:44 PM
$ABCL https://www.nytimes.com/2026/06/15/well/menopause-hormone-therapy-breast-cancer.html?unlocked_article_code=1.qVA.Mvh3.c2Z2wDdOTjnc&smid=url-share
0 · Reply
tradersunion353
tradersunion353 Jun. 16 at 12:31 PM
$ABCL no matter how much you guys are paid but you guys are overdone pumping this POS end of the day stock price matters
0 · Reply
tradersunion353
tradersunion353 Jun. 16 at 11:25 AM
$ABCL overhypee junk will be dropping to $1 after phassee 2 data same paid pumpers will come out likr maggots and keep cheerleading we are adding and loading we dont care if it goes to zero what kind of sick mentality is this?
0 · Reply
Money_maker777
Money_maker777 Jun. 15 at 9:38 PM
$ABCL It already moved from $3 to $6 in six weeks. Saying it ‘won’t move’ after a 100% run is wild.
1 · Reply
Money_maker777
Money_maker777 Jun. 15 at 9:37 PM
$ABCL Stocks cool off after big runs. That’s structure. Only amateurs confuse consolidation with collapse.
0 · Reply
tradersunion353
tradersunion353 Jun. 15 at 9:25 PM
$ABCL no matter how many times you paid artists keep saying added and loaded this POS aint gonna move infact its crashing to 1 dollar after phase 2 data
0 · Reply
Money_maker777
Money_maker777 Jun. 15 at 7:11 PM
$ABCL Added to my portfolio, just bought another 100 share :)
0 · Reply
tradersunion353
tradersunion353 Jun. 15 at 7:05 PM
$ABCL how is that forever adding and loading working? I want see those paid artists after phase 2 data when this POS scam drops to 1 dollar.
0 · Reply
8008track
8008track Jun. 15 at 5:49 PM
$ABCL I couldn’t help myself and bought more
0 · Reply
Rastafari
Rastafari Jun. 15 at 5:25 PM
$ABCL good chance we close green!
1 · Reply
tradersunion353
tradersunion353 Jun. 15 at 5:15 PM
$ABCL What did I warnabout this overhyped underperforming scam? you see +5% to -ve 1% These paid artists can continue to pump as much as they want but this going to ashes after phase 2 data
0 · Reply
Reactor_Rebel
Reactor_Rebel Jun. 15 at 4:38 PM
Telefon rings. On the other end is the version of you who bought $ABCL early. He thanks you. Confused, you ask why. "Because every dream I'm living now started with a decision you were too afraid to make." The line goes silent. All you can hear is the cost of hesitation. 💔📈😭
0 · Reply
PolarBear1
PolarBear1 Jun. 15 at 4:34 PM
$ABCL Only 12 more trading days until Q3/26!
0 · Reply
tradersunion353
tradersunion353 Jun. 15 at 2:04 PM
$ABCL POS will make every attempt close RED I am curious these paid pumpers get restless every single day Meanwhile overhyped junk is down 83% in 5 years and down by 30% on phase1 data.
1 · Reply
Money_maker777
Money_maker777 Jun. 14 at 11:49 PM
$ABCL “nsults aren’t analysis. If you have data, present it. If not, the name‑calling doesn’t change the fundamentals.
1 · Reply
Money_maker777
Money_maker777 Jun. 14 at 11:47 PM
$ABCL Nobody is paying people to talk about a $5 biotech. If you think every green candle is a pump, you’re trading emotions, not fundamentals
0 · Reply
Money_maker777
Money_maker777 Jun. 14 at 11:47 PM
$ABCL Biotech drawdowns from 2021 are macro‑driven, not ABCL‑specific. Phase 1 is a safety readout, not an efficacy catalyst, so price action there doesn’t predict Phase 2. If you have actual scientific concerns about the target or mechanism, list them otherwise calling it junk doesn’t make it junk.
0 · Reply